US OptionsDetailed Quotes
OPRX241220C10000
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover0.00%IV103.67%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma14.03Leverage Ratio--Theta--Rho--Eff Leverage--Vega
OptimizeRx Stock Discussion
Sign in to post a comment
$OptimizeRx (OPRX.US)$
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
OptimizeRx Corp. (Nasdaq: OPRX) has expanded its strategic relationship with a major pharma client, resulting in a multi-solution, multi-brand program with a total in-year commitment of over $10 million. This includes the previously mentioned $6 million DAAP contract, which is still undergoing ...
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
OptimizeRx Corp. (Nasdaq: OPRX) has expanded its strategic relationship with a major pharma client, resulting in a multi-solution, multi-brand program with a total in-year commitment of over $10 million. This includes the previously mentioned $6 million DAAP contract, which is still undergoing ...
Recent insider selling at OptimizeRx, especially by Marion Odence-Ford, may worry potential investors. The absence of insider buying and insignificant share ownership by insiders hint at possible doubts about future performance.
2
OptimizeRx's high P/S ratio may suggest that investors anticipate a turnaround in the company's revenue performance. This could indicate shareholders' strong future revenue expectations.
The high P/S ratio at OptimizeRx suggests investors expect a reversal of the company's downtrend in revenue. Shareholders seem to hold stocks with hope for the company's promising future.
Investors at OptimizeRx might be anticipating a reversal in its poor revenue performance, hence the high P/S ratio. Shareholders potentially retain stocks expecting the company's bright future.
Investors at OptimizeRx may be expecting a turnaround in the company's poor revenue performance, hence the high P/S ratio. This could reflect shareholders' strong future revenue expectations.
Analysts exhibit growing optimism towards OptimizeRx, driven by notable hike in revenue expectations. The current market conditions indicate a potential good time for reassessing OptimizeRx.
Gainers:
In reaction to earnings/guidance:
• $The Trade Desk (TTD.US)$+17%, $Workiva (WK.US)$ +15.3%, $Arlo Technologies (ARLO.US)$ +12%, $Array Technologies (ARRY.US)$ +10.3%, $Everbridge (EVBG.US)$ +9.7%, $Catalyst Pharmaceuticals (CPRX.US)$ +9.4%, $Halozyme Therapeutics (HALO.US)$ +8.7%, $Velo3D (VLD.US)$ +7.6%, $CyberArk (CYBR.US)$ + 6.2%, $Haemonetics (HAE.US)$ +5.8%, $Jackson Financial (JXN.US)$ +5.7% (also increases dividend), $Axon Enterprise (AXON.US)$ +4.8%, ...
In reaction to earnings/guidance:
• $The Trade Desk (TTD.US)$+17%, $Workiva (WK.US)$ +15.3%, $Arlo Technologies (ARLO.US)$ +12%, $Array Technologies (ARRY.US)$ +10.3%, $Everbridge (EVBG.US)$ +9.7%, $Catalyst Pharmaceuticals (CPRX.US)$ +9.4%, $Halozyme Therapeutics (HALO.US)$ +8.7%, $Velo3D (VLD.US)$ +7.6%, $CyberArk (CYBR.US)$ + 6.2%, $Haemonetics (HAE.US)$ +5.8%, $Jackson Financial (JXN.US)$ +5.7% (also increases dividend), $Axon Enterprise (AXON.US)$ +4.8%, ...
11
3
5
CAN I AT LEAST LEAST LEATHER HOW TO BUY N SELL STOCKS ON THIS BROCHURE MOOMOO 
FOR REAL I DONT GET IT 
Upgrades
• $Allogene Therapeutics (ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX (CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp (CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $TechnipFMC (FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern (NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...
• $Allogene Therapeutics (ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX (CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp (CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $TechnipFMC (FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern (NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...
14
1
4
No comment yet
MARKET-TEST-DUMMY OP :